ASEAN Vaccine Manufacturing Research Project
No hay miniatura disponible
Fecha
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Washington, DC: World Bank
Resumen
Descripción
The COVID-19 pandemic has had a
devastating effect on the ASEAN region, which has recorded
over 27 million cases of the virus. Despite rapid
development of a range of COVID-19 vaccines using innovative
technologies, access to these vaccines has been a challenge,
with manufacturing mostly concentrated in the US and Europe
for high-value mRNA vaccines, and China and India for
traditional platforms and high-volume production. Countries
with domestic COVID-19 vaccine manufacturing capacity
prioritized domestic vaccine requirements over foreign
needs, putting countries with limited production
capabilities at a disadvantage. ASEAN countries, which
overall have made limited investments in research and
development of vaccines and biologicals, were highly
dependent on imports, resulting in heightened vulnerability
during COVID 19 surges. Despite the existence of an
established framework for ASEAN coordination on vaccines,
there has been minimal coordination between member states to
collectively procure COVID-19 vaccines. Consequently, ASEAN
countries have experienced a common set of challenges in
navigating the complex global vaccine market to ramp up
COVID-19 vaccination. Leaders of ASEAN member states have
recognized the need for the region to be self-sufficient in
vaccine research and manufacturing to effectively address
future pandemics and build regional vaccine security. ASEAN
must build regional capacity to develop, test efficacy, and
scale up manufacture of vaccines, building on existing
country-level strengths and avoiding duplication.
Palabras clave
COVID-19, VACCINE, ASEAN REGION